Morse Asset Management Inc reduced its position in Emergent Biosolutions Inc. (NYSE:EBS – Free Report) by 84.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,395 shares of the biopharmaceutical company’s stock after selling 153,939 shares during the quarter. Morse Asset Management Inc’s holdings in Emergent Biosolutions were worth $194,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at approximately $29,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth approximately $36,000. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter worth approximately $44,000. Tocqueville Asset Management L.P. bought a new position in Emergent Biosolutions in the second quarter valued at approximately $93,000. Finally, Vise Technologies Inc. bought a new position in Emergent Biosolutions in the third quarter valued at approximately $96,000. 78.40% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
EBS has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Zacks Research raised Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. began coverage on Emergent Biosolutions in a report on Friday, August 21st. They issued an “underweight” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Emergent Biosolutions currently has a consensus rating of “Hold” and an average price target of $10.00.
Get Our Latest Analysis on Emergent Biosolutions
Insider Activity
In other news, Director Donald Degolyer sold 17,800 shares of Emergent Biosolutions stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total transaction of $126,202.00. Following the transaction, the director owned 111,921 shares in the company, valued at approximately $793,519.89. The trade was a 13.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.
Emergent Biosolutions Trading Down 0.1%
Shares of NYSE EBS opened at $5.79 on Tuesday. The company has a 50 day simple moving average of $6.49 and a 200 day simple moving average of $7.74. The company has a current ratio of 4.58, a quick ratio of 2.27 and a debt-to-equity ratio of 1.62. Emergent Biosolutions Inc. has a 1 year low of $4.36 and a 1 year high of $14.06.
Emergent Biosolutions (NYSE:EBS – Get Free Report) last posted its earnings results on Monday, November 2nd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Emergent Biosolutions had a negative net margin of 40.16% and a negative return on equity of 0.43%. The firm had revenue of $110.00 million for the quarter, compared to analyst estimates of $123.22 million. Equities research analysts anticipate that Emergent Biosolutions Inc. will post 0.13 EPS for the current fiscal year.
Emergent Biosolutions Profile
Emergent BioSolutions is a biopharmaceutical company focused on products that address public health threats and medical emergencies. Its portfolio includes vaccines and treatments for infectious diseases, opioid overdose and other health risks, with customers that include governments and healthcare providers. Products associated with the company include BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; and NARCAN, a naloxone nasal spray used to reverse opioid overdose. Emergent also provides contract development and manufacturing services for pharmaceutical and biotechnology organizations.
Further Reading
- Five stocks we like better than Emergent Biosolutions
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS – Free Report).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
